This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.
Participants voluntarily agree to participate in the study and sign the Informed Consent Form (ICF).
Participants aged 18 years or older (inclusive), without gender limitation.
Participants with ECOG performance score of 0 ~ 1.
Participants with expected survival time of more than 3 months.
Participants with 2 or more malignancies (except effectively treated non-melanoma skin cancer, cervical carcinoma in situ or other tumors, or malignancies considered cured) within 5 years prior to sign the Informed Consent Form.
Medication of nitrosourea or mitomycin C within 6 weeks prior to the first dose of MHB036C;
Medication of oral fluoropyrimidines or small molecule targeted agents within 5 half-lives of such drug before first dose of investigational product.
Medication of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose of investigational product.